MALAT1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression

Glioblastoma multiforme (GBM) is the most malignant brain tumor with limited therapeutic options. Temozolomide (TMZ) is a novel cytotoxic agent used as first-line chemotherapy for GBM, however, some individual cells can't be isolated for surgical resection and show treatment-resistance, thus in...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Wei, Xu, Xin-Ke, Li, Jun-Liang, Kong, Kuan-Kei, Li, Hui, Chen, Cheng, He, Jing, Wang, Fangyu, Li, Ping, Ge, Xiao-Song, Li, Fang-Cheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5410262/
https://www.ncbi.nlm.nih.gov/pubmed/28187000
http://dx.doi.org/10.18632/oncotarget.15199

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5410262/
https://www.ncbi.nlm.nih.gov/pubmed/28187000
http://dx.doi.org/10.18632/oncotarget.15199

Ejemplares similares